Healthcare Industry News:  HEALTHPOINT 

Devices Wound Care

 News Release - May 31, 2006

Quick-Med Technologies, Inc. Receives Wound Healing Society's Prestigious Blue Ribbon Award

NIMBUS(TM) in Focus at This Year's Wound Healing Society Annual Meeting

GAINESVILLE, Fla.--(HSMN NewsFeed)--May 31, 2006--Quick-Med Technologies, Inc. (OTCBB:QMDT ; "Quick-Med Technologies" or "QMT") is pleased to announce that Bernd Liesenfeld, Ph.D., senior scientist at QMT, received the Blue Ribbon Award at the Wound Healing Society's 16th Annual Meeting for the outstanding abstract entitled: "A Novel Moist Wound Healing Dressing that Provides Sustained Antimicrobial Activity and Protease Inhibition to Speed Healing". The abstract was sponsored by Quick-Med Technologies and the University of Florida at Gainesville.

The Wound Healing Society offers the Blue Ribbon Industrial Research & Development Award in recognition of research showing the mechanisms of action or efficacy for advanced new products. This competition was designed to provide recognition for the best product-oriented research performed by research and development scientists within the corporate world. Other participants at the event were prominent companies such as Johnson & Johnson Wound Management, Convatec Wound Therapeutics(TM), and HEALTHPOINT, Ltd., as well as the Harvard Medical School.

"This is a significant recognition by the thought leaders in the field of wound healing. The combination of a novel microbiocidal coating and a soluble metalloprotease inhibitor has the potential to be an important advance in wound dressings for both military and civilian applications," stated Professor Gregory S. Schultz Ph.D., Vice President of Clinical Research & Development of Quick-Med Technologies and a Professor of Obstetrics and Gynecology at the University of Florida.

The abstract represents work done in conjunction with a Small Business Innovative Research (SBIR) Phase I award from the U.S. Army Medical Research and Material Command granted to Quick-Med Technologies (1)(2), specifically to promote healing of vesicant (i.e. chemical blister agent burns) injuries. The novel dressing consists of a superabsorbent substrate treated with a non-leachable polycationic biocide coupled with a diffusible protease inhibitor/antibiotic. The dressing has commercial applications to a wide variety of acute and chronic wounds. The abstract poster in its entirety can be accessed at http://www.quickmedtech.com.

"Our team is greatly honored by this recognition from such a prestigious body as the Wound Healing Society," stated Dr. Liesenfeld, Senior Polymer Chemist of Quick-Med Technologies. "It's exciting to work on projects where the goal is so rewarding in both a scientific and social sense," added Dr. Liesenfeld.

Source:

(1) Quick-Med Technologies, Inc. Awarded U.S. Army SBIR Phase I Contract - November 15, 2005 Press Release

(2) This work is supported by the U.S. Army Medical Research and Material Command under Contract No. W81XWH-06-C-0024.

About the Wound Healing Society

The Wound Healing Society is a non-profit organization composed of clinical and basic scientists. The Society provides a forum for interaction among scientists, physicians, licensed practitioners, industrial representatives and government agencies. Founded in 1990, the Society is recognized among professionals and government agencies as the leading scientific organization focused in this area of wound healing. The Society publishes the leading journal in this area, Wound Repair and Regeneration.

About Quick-Med Technologies, Inc.

Quick-Med Technologies, Inc. is a life sciences company focused on developing broad-based technologies within the healthcare and consumer markets. The Company's two core products under development are: (1) the MultiStat(TM) family of advanced patented methods and compounds, shown to be effective in key skin care therapy applications for cosmetic, military, and medical markets; and (2) NIMBUS(TM), a technology employing advanced polymers that can be used in a wide range of applications from advanced wound care to industrial and consumer products. Quick-Med Technologies, Inc. is listed under the symbol "QMDT" on the OTC Bulletin Board. For additional information, visit Quick-Med Technologies' website: http://www.quickmedtech.com or email at info@quickmedtech.com.

For Details, Contact: David S. Lerner, President at 561-750-4202. For Investor Relations, Contact: Natasha A. Sorobey at 561-208-8259.

2006 Quick-Med Technologies, Inc. All rights reserved. NIMBUS(TM) and MultiStat(TM) are trademarks of Quick-Med Technologies, Inc. All other trademarks are the property of their respective owners.

This news release may contain "forward-looking" statements, which are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995, and include words such as "anticipates," "expects," "intends," "plans," "believes," "may," "will" or similar expressions that are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. Such statements may include, without limitation, statements concerning the Company's business model and outlook, management's ability to execute its business plan, its ability to adequately fund its operations, its ability to successfully commercialize its technologies and/or products, its ability to protect, obtain and/or develop intellectual property rights and proprietary technology, the level of acceptance and satisfaction of its licensed products and services by end-users, and its ability to manage changing technologies and markets. Such statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, the Company's actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors, including whether the Company will ever successfully launch its potential technologies and/or products, and the risk factors contained in its periodic and other filings, which are available for review at www.sec.gov. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events, or circumstances after the date of such statement.

The views, opinions and/or findings contained in this press release are those of the author(s) and should not be construed as an official Department of the U.S. Army position, policy or decision unless so designated by other documentation."


Source: Quick-Med Technologies

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.